Skip to main content
SpringerLink
Log in

Resistin, Obesity, and Cancer

  • Chapter
  • First Online:
Adipocytokines, Energy Balance, and Cancer

Part of the book series: Energy Balance and Cancer ((EBAC,volume 12))

Abstract

Obesity, a major global epidemic of this century, is associated with type 2 diabetes, cardiovascular diseases, and various types of cancer. Cancer is among the leading causes of morbidity and mortality worldwide. Many adipose tissue-derived biomarkers are associated with risks of cancer. Resistin is an adipokine produced mainly by adipocytes in mice, but monocytes and macrophages in human. Resistin was initially recognized as a regulator of insulin resistance and inflammation. There has been increasing evidence suggesting an association between increased resistin levels and obesity, as well as obesity-related disorders, such as diabetes, cardiovascular diseases, and malignancies. In particular, studies have reported higher circulating resistin levels in patients with certain types of cancer including breast cancer, colorectal cancer, lung cancer, hematologic malignancies, endometrial cancer, and pancreatic cancer, but contradictory results have also been documented. Although our understandings of the causal role and the underlying mechanisms of resistin in cancer progression and metastasis remain incomplete, resistin has been found to promote proliferation, migration, and invasiveness of a number of cancer cell lines. Furthermore, as a key inflammatory biomarker and mediator of insulin resistance, resistin may indirectly mediate cancer development through its metabolic effects. In this chapter, we summarize the current findings on the pathophysiological implications of resistin in obesity and related diseases from experimental, clinical, and epidemiological perspectives in order to decipher its role in linking obesity, insulin resistance, and inflammation to cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. WHO (2015) Global Health Observatory (GHO) data. Overweight and obesity. Available from: http://www.who.int/gho/ncd/risk_factors/overweight/en/

  2. Kahn BB, Flier JS (2000) Obesity and insulin resistance. J Clin Invest 106(4):473–481

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Vandevijvere S, Chow CC, Hall KD, Umali E, Swinburn BA (2015) Increased food energy supply as a major driver of the obesity epidemic: a global analysis. Bull World Health Organ 93(7):446–456

    Article  PubMed  PubMed Central  Google Scholar 

  4. Park HK, Ahima RS (2013) Resistin in rodents and humans. Diabetes Metabol J 37(6):404–414

    Article  Google Scholar 

  5. Steppan CM, Lazar MA (2004) The current biology of resistin. J Intern Med 255(4):439–447

    Article  CAS  PubMed  Google Scholar 

  6. Schwartz DR, Lazar MA (2011) Human resistin: found in translation from mouse to man. Trends Endocrinol Metabol 22(7):259–265

    CAS  Google Scholar 

  7. Banerjee RR, Lazar MA (2003) Resistin: molecular history and prognosis. J Mol Med 81(4):218–226

    CAS  PubMed  Google Scholar 

  8. Gallagher EJ, Fierz Y, Ferguson RD, LeRoith D (2010) The pathway from diabetes and obesity to cancer, on the route to targeted therapy. Endocr Pract 16(5):864–873

    Article  PubMed  Google Scholar 

  9. Arnold M, Pandeya N, Byrnes G, Renehan AG, Stevens GA, Ezzati M et al (2015) Global burden of cancer attributable to high body-mass index in 2012: a population-based study. Lancet Oncol 16(1):36–46

    Article  PubMed  Google Scholar 

  10. Trayhurn P, Bing C, Wood IS (2006) Adipose tissue and adipokines—energy regulation from the human perspective. J Nutr 136(7 Suppl):1935S–1939S

    CAS  PubMed  Google Scholar 

  11. Dalamaga M, Diakopoulos KN, Mantzoros CS (2012) The role of adiponectin in cancer: a review of current evidence. Endocr Rev 33(4):547–594

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Vansaun MN (2013) Molecular pathways: adiponectin and leptin signaling in cancer. Clin Cancer Res 19(8):1926–1932

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Codoner-Franch P, Alonso-Iglesias E (2015) Resistin: insulin resistance to malignancy. Clin Chim Acta 438:46–54

    Article  CAS  PubMed  Google Scholar 

  14. Dalamaga M (2014) Resistin as a biomarker linking obesity and inflammation to cancer: potential clinical perspectives. Biomark Med 8(1):107–118

    Article  CAS  PubMed  Google Scholar 

  15. Feng Z, Zhang H (2011) Resistin and cancer risk: a mini-review. Endocrinol Metab Synd. S4(003).

    Google Scholar 

  16. Steppan CM, Bailey ST, Bhat S, Brown EJ, Banerjee RR, Wright CM et al (2001) The hormone resistin links obesity to diabetes. Nature 409(6818):307–312

    Article  CAS  PubMed  Google Scholar 

  17. Yang RZ, Huang Q, Xu A, McLenithan JC, Eisen JA, Shuldiner AR et al (2003) Comparative studies of resistin expression and phylogenomics in human and mouse. Biochem Biophys Res Commun 310(3):927–935

    Article  CAS  PubMed  Google Scholar 

  18. Gallagher EJ, LeRoith D (2015) Obesity and diabetes: the increased risk of cancer and cancer-related mortality. Physiol Rev 95(3):727–748

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY et al (2001) A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci U S A 98(2):502–506

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Holcomb IN, Kabakoff RC, Chan B, Baker TW, Gurney A, Henzel W et al (2000) FIZZ1, a novel cysteine-rich secreted protein associated with pulmonary inflammation, defines a new gene family. EMBO J 19(15):4046–4055

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Kim KH, Lee K, Moon YS, Sul HS (2001) A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation. J Biol Chem 276(14):11252–11256

    Article  CAS  PubMed  Google Scholar 

  22. Ghosh S, Singh AK, Aruna B, Mukhopadhyay S, Ehtesham NZ (2003) The genomic organization of mouse resistin reveals major differences from the human resistin: functional implications. Gene 305(1):27–34

    Article  CAS  PubMed  Google Scholar 

  23. Hartman HB, Hu X, Tyler KX, Dalal CK, Lazar MA (2002) Mechanisms regulating adipocyte expression of resistin. J Biol Chem 277(22):19754–19761

    Article  CAS  PubMed  Google Scholar 

  24. Tomaru T, Steger DJ, Lefterova MI, Schupp M, Lazar MA (2009) Adipocyte-specific expression of murine resistin is mediated by synergism between peroxisome proliferator-activated receptor gamma and CCAAT/enhancer-binding proteins. J Biol Chem 284(10):6116–6125

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Patel SD, Rajala MW, Rossetti L, Scherer PE, Shapiro L (2004) Disulfide-dependent multimeric assembly of resistin family hormones. Science 304(5674):1154–8

    Article  CAS  PubMed  Google Scholar 

  26. Graveleau C, Zaha VG, Mohajer A, Banerjee RR, Dudley-Rucker N, Steppan CM et al (2005) Mouse and human resistins impair glucose transport in primary mouse cardiomyocytes, and oligomerization is required for this biological action. J Biol Chem 280(36):31679–31685

    Article  CAS  PubMed  Google Scholar 

  27. Savage DB, Sewter CP, Klenk ES, Segal DG, Vidal-Puig A, Considine RV et al (2001) Resistin / Fizz3 expression in relation to obesity and peroxisome proliferator-activated receptor-gamma action in humans. Diabetes 50(10):2199–2202

    Article  CAS  PubMed  Google Scholar 

  28. Jung HS, Park KH, Cho YM, Chung SS, Cho HJ, Cho SY et al (2006) Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69(1):76–85

    Article  CAS  PubMed  Google Scholar 

  29. Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C et al (2003) Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun 300(2):472–476

    Article  CAS  PubMed  Google Scholar 

  30. Fain JN, Cheema PS, Bahouth SW, Lloyd HM (2003) Resistin release by human adipose tissue explants in primary culture. Biochem Biophys Res Commun 300(3):674–678

    Article  CAS  PubMed  Google Scholar 

  31. Aruna B, Islam A, Ghosh S, Singh AK, Vijayalakshmi M, Ahmad F et al (2008) Biophysical analyses of human resistin: oligomer formation suggests novel biological function. Biochemistry 47(47):12457–12466

    Article  CAS  PubMed  Google Scholar 

  32. Gerber M, Boettner A, Seidel B, Lammert A, Bar J, Schuster E et al (2005) Serum resistin levels of obese and lean children and adolescents: biochemical analysis and clinical relevance. J Clin Endocrinol Metab 90(8):4503–4509

    Article  CAS  PubMed  Google Scholar 

  33. Daquinag AC, Zhang Y, Amaya-Manzanares F, Simmons PJ, Kolonin MG (2011) An isoform of decorin is a resistin receptor on the surface of adipose progenitor cells. Cell Stem Cell 9(1):74–86

    Article  CAS  PubMed  Google Scholar 

  34. Sanchez-Solana B, Laborda J, Baladron V (2012) Mouse resistin modulates adipogenesis and glucose uptake in 3T3-L1 preadipocytes through the ROR1 receptor. Mol Endocrinol 26(1):110–27

    Article  CAS  PubMed  Google Scholar 

  35. Tarkowski A, Bjersing J, Shestakov A, Bokarewa MI (2010) Resistin competes with lipopolysaccharide for binding to toll-like receptor 4. J Cell Mol Med 14(6b):1419–1431

    Article  CAS  PubMed  Google Scholar 

  36. Lee S, Lee HC, Kwon YW, Lee SE, Cho Y, Kim J et al (2014) Adenylyl cyclase-associated protein 1 is a receptor for human resistin and mediates inflammatory actions of human monocytes. Cell Metab 19(3):484–497

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Hubberstey AV, Mottillo EP (2002) Cyclase-associated proteins: CAPacity for linking signal transduction and actin polymerization. FASEB J 16(6):487–499

    Article  CAS  PubMed  Google Scholar 

  38. Park HK, Qatanani M, Briggs ER, Ahima RS, Lazar MA (2011) Inflammatory induction of human resistin causes insulin resistance in endotoxemic mice. Diabetes 60(3):775–783

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M et al (2002) Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells. Diabetes 51(6):1737–1744

    Article  CAS  PubMed  Google Scholar 

  40. Kim SJ, Nian C, McIntosh CH (2007) Resistin is a key mediator of glucose-dependent insulinotropic polypeptide (GIP) stimulation of lipoprotein lipase (LPL) activity in adipocytes. J Biol Chem 282(47):34139–34147

    Article  CAS  PubMed  Google Scholar 

  41. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R (2001) Tumor necrosis factor alpha is a negative regulator of resistin gene expression and secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 288(4):1027–1031

    Article  CAS  PubMed  Google Scholar 

  42. Zhong Q, Lin CY, Clarke KJ, Kemppainen RJ, Schwartz DD, Judd RL (2002) Endothelin-1 inhibits resistin secretion in 3T3-L1 adipocytes. Biochem Biophys Res Commun 296(2):383–387

    Article  CAS  PubMed  Google Scholar 

  43. Steppan CM, Wang J, Whiteman EL, Birnbaum MJ, Lazar MA (2005) Activation of SOCS-3 by resistin. Mol Cell Biol 25(4):1569–1575

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Kim SJ, Nian C, McIntosh CH (2013) Resistin knockout mice exhibit impaired adipocyte glucose-dependent insulinotropic polypeptide receptor (GIPR) expression. Diabetes 62(2):471–477

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Song R, Wang X, Mao Y, Li H, Li Z, Xu W et al (2013) Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3beta. Gene 529(1):50–56

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Palanivel R, Maida A, Liu Y, Sweeney G (2006) Regulation of insulin signalling, glucose uptake and metabolism in rat skeletal muscle cells upon prolonged exposure to resistin. Diabetologia 49(1):183–190

    Article  CAS  PubMed  Google Scholar 

  47. Fan HQ, Gu N, Liu F, Fei L, Pan XQ, Guo M et al (2007) Prolonged exposure to resistin inhibits glucose uptake in rat skeletal muscles. Acta Pharmacol Sin 28(3):410–416

    Article  CAS  PubMed  Google Scholar 

  48. Zachariah Tom R, Garcia-Roves PM, Sjogren RJ, Jiang LQ, Holmstrom MH, Deshmukh AS et al (2014) Effects of AMPK activation on insulin sensitivity and metabolism in leptin-deficient ob/ob mice. Diabetes 63(5):1560–1571

    Article  PubMed  CAS  Google Scholar 

  49. Muse ED, Obici S, Bhanot S, Monia BP, McKay RA, Rajala MW et al (2004) Role of resistin in diet-induced hepatic insulin resistance. J Clin Invest 114(2):232–239

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  50. Satoh H, Nguyen MT, Miles PD, Imamura T, Usui I, Olefsky JM (2004) Adenovirus-mediated chronic “hyper-resistinemia” leads to in vivo insulin resistance in normal rats. J Clin Invest 114(2):224–231

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Li FP, He J, Li ZZ, Luo ZF, Yan L, Li Y (2009) Effects of resistin expression on glucose metabolism and hepatic insulin resistance. Endocrine 35(2):243–251

    Article  CAS  PubMed  Google Scholar 

  52. Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y et al (2004) Regulation of fasted blood glucose by resistin. Science 303(5661):1195–8

    Article  CAS  PubMed  Google Scholar 

  53. Qi Y, Nie Z, Lee YS, Singhal NS, Scherer PE, Lazar MA et al (2006) Loss of resistin improves glucose homeostasis in leptin deficiency. Diabetes 55(11):3083–3090

    Article  CAS  PubMed  Google Scholar 

  54. Tovar S, Nogueiras R, Tung LY, Castaneda TR, Vazquez MJ, Morris A et al (2005) Central administration of resistin promotes short-term satiety in rats. Eur J Endocrinol 153(3):R1–R5

    Article  CAS  PubMed  Google Scholar 

  55. Way JM, Gorgun CZ, Tong Q, Uysal KT, Brown KK, Harrington WW et al (2001) Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists. J Biol Chem 276(28):25651–25653

    Article  CAS  PubMed  Google Scholar 

  56. Ye H, Zhang HJ, Xu A, Hoo RL (2013) Resistin production from adipose tissue is decreased in db/db obese mice, and is reversed by rosiglitazone. PLoS One 8(6):e65543

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Rajala MW, Lin Y, Ranalletta M, Yang XM, Qian H, Gingerich R et al (2002) Cell type-specific expression and coregulation of murine resistin and resistin-like molecule-alpha in adipose tissue. Mol Endocrinol 16(8):1920–1930

    Article  CAS  PubMed  Google Scholar 

  58. Haluzik MM, Lacinova Z, Dolinkova M, Haluzikova D, Housa D, Horinek A et al (2006) Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels. Endocrinology 147(9):4517–4524

    Article  CAS  PubMed  Google Scholar 

  59. Lehrke M, Reilly MP, Millington SC, Iqbal N, Rader DJ, Lazar MA (2004) An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1(2):e45

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  60. Furugen R, Hayashida H, Yoshii Y, Saito T (2011) Neutrophil-derived resistin release induced by Aggregatibacter actinomycetemcomitans. FEMS Microbiol Lett 321(2):175–182

    Article  CAS  PubMed  Google Scholar 

  61. Bostrom EA, Tarkowski A, Bokarewa M (2009) Resistin is stored in neutrophil granules being released upon challenge with inflammatory stimuli. Biochim Biophys Acta 1793(12):1894–1900

    Article  PubMed  CAS  Google Scholar 

  62. Minn AH, Patterson NB, Pack S, Hoffmann SC, Gavrilova O, Vinson C et al (2003) Resistin is expressed in pancreatic islets. Biochem Biophys Res Commun 310(2):641–645

    Article  CAS  PubMed  Google Scholar 

  63. Thommesen L, Stunes AK, Monjo M, Grosvik K, Tamburstuen MV, Kjobli E et al (2006) Expression and regulation of resistin in osteoblasts and osteoclasts indicate a role in bone metabolism. J Cell Biochem 99(3):824–834

    Article  CAS  PubMed  Google Scholar 

  64. Senolt L, Housa D, Vernerova Z, Jirasek T, Svobodova R, Veigl D et al (2007) Resistin in rheumatoid arthritis synovial tissue, synovial fluid and serum. Ann Rheum Dis 66(4):458–463

    Article  CAS  PubMed  Google Scholar 

  65. Yura S, Sagawa N, Itoh H, Kakui K, Nuamah MA, Korita D et al (2003) Resistin is expressed in the human placenta. J Clin Endocrinol Metab 88(3):1394–1397

    Article  PubMed  Google Scholar 

  66. Kim HJ, Lee YS, Won EH, Chang IH, Kim TH, Park ES et al (2011) Expression of resistin in the prostate and its stimulatory effect on prostate cancer cell proliferation. BJU Int 108(2 Pt 2):E77–E83

    Article  PubMed  Google Scholar 

  67. Kuo CH, Chen KF, Chou SH, Huang YF, Wu CY, Cheng DE et al (2013) Lung tumor-associated dendritic cell-derived resistin promoted cancer progression by increasing Wolf-Hirschhorn syndrome candidate 1/Twist pathway. Carcinogenesis 34(11):2600–2609

    Article  CAS  PubMed  Google Scholar 

  68. Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR (2003) Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun 309(2):286–290

    Article  CAS  PubMed  Google Scholar 

  69. Lu SC, Shieh WY, Chen CY, Hsu SC, Chen HL (2002) Lipopolysaccharide increases resistin gene expression in vivo and in vitro. FEBS Lett 530(1-3):158–162

    Article  CAS  PubMed  Google Scholar 

  70. Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A (2005) Resistin, an adipokine with potent proinflammatory properties. J Immunol 174(9):5789–5795

    Article  CAS  PubMed  Google Scholar 

  71. Reilly MP, Lehrke M, Wolfe ML, Rohatgi A, Lazar MA, Rader DJ (2005) Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111(7):932–939

    Article  CAS  PubMed  Google Scholar 

  72. Walcher D, Hess K, Berger R, Aleksic M, Heinz P, Bach H et al (2010) Resistin: a newly identified chemokine for human CD4-positive lymphocytes. Cardiovasc Res 85(1):167–174

    Article  CAS  PubMed  Google Scholar 

  73. Jiang S, Park DW, Tadie JM, Gregoire M, Deshane J, Pittet JF et al (2014) Human resistin promotes neutrophil proinflammatory activation and neutrophil extracellular trap formation and increases severity of acute lung injury. J Immunol 192(10):4795–4803

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  74. Melone M, Wilsie L, Palyha O, Strack A, Rashid S (2012) Discovery of a new role of human resistin in hepatocyte low-density lipoprotein receptor suppression mediated in part by proprotein convertase subtilisin/kexin type 9. J Am Coll Cardiol 59(19):1697–1705

    Article  CAS  PubMed  Google Scholar 

  75. Samaha FF, Szapary PO, Iqbal N, Williams MM, Bloedon LT, Kochar A et al (2006) Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome. Arterioscler Thromb Vasc Biol 26(3):624–630

    Article  CAS  PubMed  Google Scholar 

  76. Azuma K, Katsukawa F, Oguchi S, Murata M, Yamazaki H, Shimada A et al (2003) Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11(8):997–1001

    Article  CAS  PubMed  Google Scholar 

  77. Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S et al (2009) Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 51(4):765–777

    Article  CAS  PubMed  Google Scholar 

  78. de Luis DA, Terroba MC, Cuellar L, Conde R, Primo D, Aller R et al (2011) Resistin levels in morbid obese patients following the biliopancreatic diversion surgery. Horm Metab Res 43(3):205–8

    Article  PubMed  CAS  Google Scholar 

  79. McTernan PG, Fisher FM, Valsamakis G, Chetty R, Harte A, McTernan CL et al (2003) Resistin and type 2 diabetes: regulation of resistin expression by insulin and rosiglitazone and the effects of recombinant resistin on lipid and glucose metabolism in human differentiated adipocytes. J Clin Endocrinol Metab 88(12):6098–6106

    Article  CAS  PubMed  Google Scholar 

  80. Lee JH, Chan JL, Yiannakouris N, Kontogianni M, Estrada E, Seip R et al (2003) Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88(10):4848–4856

    Article  CAS  PubMed  Google Scholar 

  81. Burnett MS, Lee CW, Kinnaird TD, Stabile E, Durrani S, Dullum MK et al (2005) The potential role of resistin in atherogenesis. Atherosclerosis 182(2):241–248

    Article  CAS  PubMed  Google Scholar 

  82. Cho Y, Lee SE, Lee HC, Hur J, Lee S, Youn SW et al (2011) Adipokine resistin is a key player to modulate monocytes, endothelial cells, and smooth muscle cells, leading to progression of atherosclerosis in rabbit carotid artery. J Am Coll Cardiol 57(1):99–109

    Article  CAS  PubMed  Google Scholar 

  83. Hsu WY, Chao YW, Tsai YL, Lien CC, Chang CF, Deng MC et al (2011) Resistin induces monocyte-endothelial cell adhesion by increasing ICAM-1 and VCAM-1 expression in endothelial cells via p38MAPK-dependent pathway. J Cell Physiol 226(8):2181–2188

    Article  CAS  PubMed  Google Scholar 

  84. Ou HC, Lee WJ, Wu CM, Chen JF, Sheu WH (2012) Aspirin prevents resistin-induced endothelial dysfunction by modulating AMPK, ROS, and Akt/eNOS signaling. J Vasc Surg 55(4):1104–1115

    Article  PubMed  Google Scholar 

  85. Jamaluddin MS, Yan S, Lu J, Liang Z, Yao Q, Chen C (2013) Resistin increases monolayer permeability of human coronary artery endothelial cells. PLoS One 8(12), e84576

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  86. Calabro P, Samudio I, Willerson JT, Yeh ET (2004) Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation 110(21):3335–3340

    Article  CAS  PubMed  Google Scholar 

  87. Kang SW, Kim MS, Kim HS, Kim Y, Shin D, Park JH et al (2013) Celastrol attenuates adipokine resistin-associated matrix interaction and migration of vascular smooth muscle cells. J Cell Biochem 114(2):398–408

    Article  CAS  PubMed  Google Scholar 

  88. Menzaghi C, Trischitta V (2010) Genetics of serum resistin: a paradigm of population-specific regulation? Diabetologia 53(2):226–228

    Article  CAS  PubMed  Google Scholar 

  89. Hussain S, Bibi S, Javed Q (2011) Heritability of genetic variants of resistin gene in patients with coronary artery disease: a family-based study. Clin Biochem 44(8-9):618–622

    Article  CAS  PubMed  Google Scholar 

  90. Smith SR, Bai F, Charbonneau C, Janderova L, Argyropoulos G (2003) A promoter genotype and oxidative stress potentially link resistin to human insulin resistance. Diabetes 52(7):1611–1618

    Article  CAS  PubMed  Google Scholar 

  91. Azuma K, Oguchi S, Matsubara Y, Mamizuka T, Murata M, Kikuchi H et al (2004) Novel resistin promoter polymorphisms: association with serum resistin level in Japanese obese individuals. Horm Metab Res 36(8):564–70

    Article  CAS  PubMed  Google Scholar 

  92. Osawa H, Yamada K, Onuma H, Murakami A, Ochi M, Kawata H et al (2004) The G/G genotype of a resistin single-nucleotide polymorphism at -420 increases type 2 diabetes mellitus susceptibility by inducing promoter activity through specific binding of Sp1/3. Am J Hum Genet 75(4):678–686

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Hivert MF, Manning AK, McAteer JB, Dupuis J, Fox CS, Cupples LA et al (2009) Association of variants in RETN with plasma resistin levels and diabetes-related traits in the Framingham Offspring Study. Diabetes 58(3):750–756

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  94. Mattevi VS, Zembrzuski VM, Hutz MH (2004) A resistin gene polymorphism is associated with body mass index in women. Hum Genet 115(3):208–212

    Article  CAS  PubMed  Google Scholar 

  95. Osawa H, Tabara Y, Kawamoto R, Ohashi J, Ochi M, Onuma H et al (2007) Plasma resistin, associated with single nucleotide polymorphism -420, is correlated with insulin resistance, lower HDL cholesterol, and high-sensitivity C-reactive protein in the Japanese general population. Diabetes Care 30(6):1501–1506

    Article  CAS  PubMed  Google Scholar 

  96. Xu JY, Sham PC, Xu A, Tso AW, Wat NM, Cheng KY et al (2007) Resistin gene polymorphisms and progression of glycaemia in southern Chinese: a 5-year prospective study. Clin Endocrinol 66(2):211–217

    Article  CAS  Google Scholar 

  97. Qasim AN, Metkus TS, Tadesse M, Lehrke M, Restine S, Wolfe ML et al (2009) Resistin gene variation is associated with systemic inflammation but not plasma adipokine levels, metabolic syndrome or coronary atherosclerosis in nondiabetic Caucasians. Clin Endocrinol 70(5):698–705

    Article  CAS  Google Scholar 

  98. Cho YM, Youn BS, Chung SS, Kim KW, Lee HK, Yu KY et al (2004) Common genetic polymorphisms in the promoter of resistin gene are major determinants of plasma resistin concentrations in humans. Diabetologia 47(3):559–565

    Article  CAS  PubMed  Google Scholar 

  99. Wagsater D, Mumtaz M, Lofgren S, Hugander A, Dimberg J (2008) Resistin in human colorectal cancer: increased expression independently of resistin promoter -420C>G genotype. Cancer Invest 26(10):1008–1014

    Article  PubMed  CAS  Google Scholar 

  100. Hlavna M, Kohut L, Lipkova J, Bienertova-Vasku J, Dostalova Z, Chovanec J et al (2011) Relationship of resistin levels with endometrial cancer risk. Neoplasma 58(2):124–128

    Article  CAS  PubMed  Google Scholar 

  101. Chung CM, Lin TH, Chen JW, Leu HB, Yin WH, Ho HY et al (2014) Common quantitative trait locus downstream of RETN gene identified by genome-wide association study is associated with risk of type 2 diabetes mellitus in Han Chinese: a Mendelian randomization effect. Diabetes Metab Res Rev 30(3):232–240

    Article  CAS  PubMed  Google Scholar 

  102. Degawa-Yamauchi M, Bovenkerk JE, Juliar BE, Watson W, Kerr K, Jones R et al (2003) Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88(11):5452–5455

    Article  CAS  PubMed  Google Scholar 

  103. Iqbal N, Seshadri P, Stern L, Loh J, Kundu S, Jafar T et al (2005) Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 9(3):161–165

    CAS  PubMed  Google Scholar 

  104. Yagmur E, Trautwein C, Gressner AM, Tacke F (2006) Resistin serum levels are associated with insulin resistance, disease severity, clinical complications, and prognosis in patients with chronic liver diseases. Am J Gastroenterol 101(6):1244–1252

    Article  CAS  PubMed  Google Scholar 

  105. Li M, Fisette A, Zhao XY, Deng JY, Mi J, Cianflone K (2009) Serum resistin correlates with central obesity but weakly with insulin resistance in Chinese children and adolescents. Int J Obes 33(4):424–439

    Article  CAS  Google Scholar 

  106. de Luis DA, Gonzalez Sagrado M, Conde R, Aller R, Izaola O, Perez Castrillon JL et al (2009) Relation of resistin levels with cardiovascular risk factors and insulin resistance in non-diabetes obese patients. Diabetes Res Clin Pract 84(2):174–178

    Article  PubMed  CAS  Google Scholar 

  107. Fujinami A, Obayashi H, Ohta K, Ichimura T, Nishimura M, Matsui H et al (2004) Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 339(1-2):57–63

    Article  CAS  PubMed  Google Scholar 

  108. Pfutzner A, Langenfeld M, Kunt T, Lobig M, Forst T (2003) Evaluation of human resistin assays with serum from patients with type 2 diabetes and different degrees of insulin resistance. Clin Lab 49(11-12):571–576

    PubMed  Google Scholar 

  109. Silha JV, Krsek M, Skrha JV, Sucharda P, Nyomba BL, Murphy LJ (2003) Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 149(4):331–335

    Article  CAS  PubMed  Google Scholar 

  110. Youn BS, Yu KY, Park HJ, Lee NS, Min SS, Youn MY et al (2004) Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 89(1):150–156

    Article  CAS  PubMed  Google Scholar 

  111. Koerner A, Kratzsch J, Kiess W (2005) Adipocytokines: leptin--the classical, resistin--the controversical, adiponectin--the promising, and more to come. Best Pract Res Clin Endocrinol Metab 19(4):525–546

    Article  CAS  PubMed  Google Scholar 

  112. American Cancer Society (2016) Cancer facts and figures 2016. American Cancer Society, Atlanta, GA

    Google Scholar 

  113. Kaaks R, Van Noord PA, Den Tonkelaar I, Peeters PH, Riboli E, Grobbee DE (1998) Breast-cancer incidence in relation to height, weight and body-fat distribution in the Dutch “DOM” cohort. Int J Cancer 76(5):647–651

    Article  CAS  PubMed  Google Scholar 

  114. Harris HR, Willett WC, Terry KL, Michels KB (2011) Body fat distribution and risk of premenopausal breast cancer in the Nurses’ Health Study II. J Natl Cancer Inst 103(3):273–278

    Article  PubMed  Google Scholar 

  115. Hou WK, Xu YX, Yu T, Zhang L, Zhang WW, Fu CL et al (2007) Adipocytokines and breast cancer risk. Chin Med J (Engl) 120(18):1592–1596

    CAS  Google Scholar 

  116. Kang JH, Yu BY, Youn DS (2007) Relationship of serum adiponectin and resistin levels with breast cancer risk. J Korean Med Sci 22(1):117–121

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  117. Sun CA, Wu MH, Chu CH, Chou YC, Hsu GC, Yang T et al (2010) Adipocytokine resistin and breast cancer risk. Breast Cancer Res Treat 123(3):869–876

    Article  CAS  PubMed  Google Scholar 

  118. Dalamaga M, Karmaniolas K, Papadavid E, Pelekanos N, Sotiropoulos G, Lekka A (2013) Hyperresistinemia is associated with postmenopausal breast cancer. Menopause 20(8):845–851

    Article  PubMed  Google Scholar 

  119. Lee YC, Chen YJ, Wu CC, Lo S, Hou MF, Yuan SS (2012) Resistin expression in breast cancer tissue as a marker of prognosis and hormone therapy stratification. Gynecol Oncol 125(3):742–750

    Article  CAS  PubMed  Google Scholar 

  120. Gaudet MM, Falk RT, Gierach GL, Lacey JV Jr, Graubard BI, Dorgan JF et al (2010) Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol 34(5):580–586

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  121. Alokail MS, Al-Daghri N, Abdulkareem A, Draz HM, Yakout SM, Alnaami AM et al (2013) Metabolic syndrome biomarkers and early breast cancer in Saudi women: evidence for the presence of a systemic stress response and/or a pre-existing metabolic syndrome-related neoplasia risk? BMC Cancer 13:54

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  122. Stewart PA, Luks J, Roycik MD, Sang QX, Zhang J (2013) Differentially expressed transcripts and dysregulated signaling pathways and networks in African American breast cancer. PLoS One 8(12):e82460

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  123. Key T, Appleby P, Barnes I, Reeves G (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94(8):606–616

    Article  CAS  PubMed  Google Scholar 

  124. Kaaks R, Berrino F, Key T, Rinaldi S, Dossus L, Biessy C et al (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97(10):755–765

    Article  CAS  PubMed  Google Scholar 

  125. Chalvatzas N, Dafopoulos K, Kosmas G, Kallitsaris A, Pournaras S, Messinis IE (2009) Effect of ovarian hormones on serum adiponectin and resistin concentrations. Fertil Steril 91(4):1189–1194

    Article  CAS  PubMed  Google Scholar 

  126. De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013:291546

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  127. Freedland SJ, Aronson WJ (2004) Examining the relationship between obesity and prostate cancer. Rev Urol 6(2):73–81

    PubMed  PubMed Central  Google Scholar 

  128. Discacciati A, Orsini N, Wolk A (2012) Body mass index and incidence of localized and advanced prostate cancer--a dose-response meta-analysis of prospective studies. Ann Oncol 23(7):1665–1671

    Article  CAS  PubMed  Google Scholar 

  129. Esposito K, Chiodini P, Capuano A, Bellastella G, Maiorino MI, Parretta E et al (2013) Effect of metabolic syndrome and its components on prostate cancer risk: meta-analysis. J Endocrinol Investig 36(2):132–139

    Article  CAS  Google Scholar 

  130. Parekh DJ, Ankerst DP, Baillargeon J, Higgins B, Platz EA, Troyer D et al (2007) Assessment of 54 biomarkers for biopsy-detectable prostate cancer. Cancer Epidemiol 16(10):1966–1972

    Article  CAS  Google Scholar 

  131. Housa D, Vernerova Z, Heracek J, Cechak P, Rosova B, Kuncova J et al (2008) Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression. Neoplasma 55(5):442–446

    CAS  PubMed  Google Scholar 

  132. Smith MR, Lee H, McGovern F, Fallon MA, Goode M, Zietman AL et al (2008) Metabolic changes during gonadotropin-releasing hormone agonist therapy for prostate cancer: differences from the classic metabolic syndrome. Cancer 112(10):2188–2194

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  133. Smith MR, Lee H, Fallon MA, Nathan DM (2008) Adipocytokines, obesity, and insulin resistance during combined androgen blockade for prostate cancer. Urology 71(2):318–322

    Article  PubMed  PubMed Central  Google Scholar 

  134. Pischon T, Lahmann PH, Boeing H, Friedenreich C, Norat T, Tjonneland A et al (2006) Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 98(13):920–931

    Article  PubMed  Google Scholar 

  135. Vazzana N, Riondino S, Toto V, Guadagni F, Roselli M, Davi G et al (2012) Obesity-driven inflammation and colorectal cancer. Curr Med Chem 19(34):5837–5853

    Article  CAS  PubMed  Google Scholar 

  136. Kumor A, Daniel P, Pietruczuk M, Malecka-Panas E (2009) Serum leptin, adiponectin, and resistin concentration in colorectal adenoma and carcinoma (CC) patients. Int J Color Dis 24(3):275–281

    Article  Google Scholar 

  137. Nakajima TE, Yamada Y, Hamano T, Furuta K, Matsuda T, Fujita S et al (2010) Adipocytokines as new promising markers of colorectal tumors: adiponectin for colorectal adenoma, and resistin and visfatin for colorectal cancer. Cancer Sci 101(5):1286–1291

    Article  CAS  PubMed  Google Scholar 

  138. Al-Harithy RN, Al-Ghafari AB (2010) Resistin in human colon cancer. Increased expression independently of resistin promoter C-180G genotype. Saudi Med J 31(5):495–500

    PubMed  Google Scholar 

  139. Gonullu G, Kahraman H, Bedir A, Bektas A, Yucel I (2010) Association between adiponectin, resistin, insulin resistance, and colorectal tumors. Int J Color Dis 25(2):205–212

    Article  Google Scholar 

  140. Salageanu A, Tucureanu C, Lerescu L, Caras I, Pitica R, Gangura G et al (2010) Serum levels of adipokines resistin and leptin in patients with colon cancer. J Med Life 3(4):416–420

    PubMed  PubMed Central  Google Scholar 

  141. Danese E, Montagnana M, Minicozzi AM, Bonafini S, Ruzzenente O, Gelati M et al (2012) The role of resistin in colorectal cancer. Clin Chim Acta 413(7-8):760–4

    Article  CAS  PubMed  Google Scholar 

  142. Joshi RK, Kim WJ, Lee SA (2014) Association between obesity-related adipokines and colorectal cancer: a case-control study and meta-analysis. World J Gastroenterol 20(24):7941–7949

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  143. Otake S, Takeda H, Fujishima S, Fukui T, Orii T, Sato T et al (2010) Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 16(10):1252–1257

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  144. Hillenbrand A, Fassler J, Huber N, Xu P, Henne-Bruns D, Templin M et al (2012) Changed adipocytokine concentrations in colorectal tumor patients and morbidly obese patients compared to healthy controls. BMC Cancer 12:545

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  145. Ho GY, Wang T, Gunter MJ, Strickler HD, Cushman M, Kaplan RC et al (2012) Adipokines linking obesity with colorectal cancer risk in postmenopausal women. Cancer Res 72(12):3029–3037

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  146. Slomian G, Swietochowska E, Malinowska-Borowska J, Kasperczyk S, Rogalska A, Nowak P (2014) Association between chemotherapy and plasma adipokines in patients with colorectal cancer. Pharmacol Rep 66(5):902–907

    Article  CAS  PubMed  Google Scholar 

  147. Kosova F, Coskun T, Kaya Y, Kara E, Ari Z (2013) Adipocytokine levels of colon cancer patients before and after treatment. Bratisl Lek Listy 114(7):394–397

    CAS  PubMed  Google Scholar 

  148. Karapanagiotou EM, Tsochatzis EA, Dilana KD, Tourkantonis I, Gratsias I, Syrigos KN (2008) The significance of leptin, adiponectin, and resistin serum levels in non-small cell lung cancer (NSCLC). Lung Cancer 61(3):391–397

    Article  PubMed  Google Scholar 

  149. Jamison PM, Noone AM, Ries LA, Lee NC, Edwards BK (2013) Trends in endometrial cancer incidence by race and histology with a correction for the prevalence of hysterectomy, SEER 1992 to 2008. Cancer Epidemiol Biomarkers Prev 22(2):233–241

    Article  PubMed  Google Scholar 

  150. Wartko P, Sherman ME, Yang HP, Felix AS, Brinton LA, Trabert B (2013) Recent changes in endometrial cancer trends among menopausal-age U.S. women. Cancer Epidemiol 37(4):374–377

    Article  PubMed  PubMed Central  Google Scholar 

  151. Jenabi E, Poorolajal J (2015) The effect of body mass index on endometrial cancer: a meta-analysis. Public Health 29(7):872–880

    Article  Google Scholar 

  152. Ilhan TT, Kebapcilar A, Yilmaz SA, Ilhan T, Kerimoglu OS, Pekin AT et al (2015) Relations of serum visfatin and resistin levels with endometrial cancer and factors associated with its prognosis. Asian Pac J Cancer Prev 16(11):4503–4508

    Article  PubMed  Google Scholar 

  153. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108

    Article  PubMed  Google Scholar 

  154. Nakajima TE, Yamada Y, Hamano T, Furuta K, Gotoda T, Katai H et al (2009) Adipocytokine levels in gastric cancer patients: resistin and visfatin as biomarkers of gastric cancer. J Gastroenterol 44(7):685–690

    Article  CAS  PubMed  Google Scholar 

  155. Nakajima TE, Yamada Y, Hamano T, Furuta K, Oda I, Kato H et al (2010) Adipocytokines and squamous cell carcinoma of the esophagus. J Cancer Res Clin Oncol 136(2):261–266

    Article  CAS  PubMed  Google Scholar 

  156. Diakowska D, Markocka-Maczka K, Szelachowski P, Grabowski K (2014) Serum levels of resistin, adiponectin, and apelin in gastroesophageal cancer patients. Dis Markers 2014:619649

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  157. Kerem M, Ferahkose Z, Yilmaz UT, Pasaoglu H, Ofluoglu E, Bedirli A et al (2008) Adipokines and ghrelin in gastric cancer cachexia. World J Gastroenterol 14(23):3633–3641

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  158. Moschovi M, Trimis G, Vounatsou M, Katsibardi K, Margeli A, Damianos A et al (2010) Serial plasma concentrations of adiponectin, leptin, and resistin during therapy in children with acute lymphoblastic leukemia. J Pediatr Hematol Oncol 32(1):e8–e13

    Article  CAS  PubMed  Google Scholar 

  159. Kohler JA, Moon RJ, Wright S, Willows E, Davies JH (2011) Increased adiposity and altered adipocyte function in female survivors of childhood acute lymphoblastic leukaemia treated without cranial radiation. Horm Res Paediatr 75(6):433–440

    Article  CAS  PubMed  Google Scholar 

  160. Pamuk GE, Demir M, Harmandar F, Yesil Y, Turgut B, Vural O (2006) Leptin and resistin levels in serum of patients with hematologic malignancies: correlation with clinical characteristics. Exp Oncol 28(3):241–244

    CAS  PubMed  Google Scholar 

  161. Dalamaga M, Karmaniolas K, Nikolaidou A, Chamberland J, Hsi A, Dionyssiou-Asteriou A et al (2008) Adiponectin and resistin are associated with risk for myelodysplastic syndrome, independently from the insulin-like growth factor-I (IGF-I) system. Eur J Cancer 44(12):1744–1753

    Article  CAS  PubMed  Google Scholar 

  162. Dalamaga M, Karmaniolas K, Panagiotou A, Hsi A, Chamberland J, Dimas C et al (2009) Low circulating adiponectin and resistin, but not leptin, levels are associated with multiple myeloma risk: a case-control study. Cancer Causes Control 20(2):193–199

    Article  PubMed  Google Scholar 

  163. Reseland JE, Reppe S, Olstad OK, Hjorth-Hansen H, Brenne AT, Syversen U et al (2009) Abnormal adipokine levels and leptin-induced changes in gene expression profiles in multiple myeloma. Eur J Haematol 83(5):460–470

    Article  CAS  PubMed  Google Scholar 

  164. Liao LM, Weinstein SJ, Pollak M, Li Z, Virtamo J, Albanes D et al (2013) Prediagnostic circulating adipokine concentrations and risk of renal cell carcinoma in male smokers. Carcinogenesis 34(1):109–112

    Article  PubMed  CAS  Google Scholar 

  165. Wang H, Maitra A, Wang H (2015) Obesity, intrapancreatic fatty infiltration, and pancreatic cancer. Clin Cancer Res 21(15):3369–3371

    Article  CAS  PubMed  Google Scholar 

  166. Al-Salam S, Rashed H, Adeghate E (2011) Diabetes mellitus is associated with an increased expression of resistin in human pancreatic islet cells. Islets 3(5):246–249

    Article  PubMed  Google Scholar 

  167. Jiang CY, Wang W, Yin YL, Yuan ZR, Wang LB (2012) Expression of the adipocytokine resistin and its association with the clinicopathological features and prognosis of pancreatic ductal adenocarcinoma. Oncol Lett 4(5):960–964

    PubMed  PubMed Central  Google Scholar 

  168. Gasiorowska A, Talar-Wojnarowska R, Kaczka A, Borkowska A, Czupryniak L, Malecka-Panas E (2013) Role of adipocytokines and its correlation with endocrine pancreatic function in patients with pancreatic cancer. Pancreatology 13(4):409–414

    Article  CAS  PubMed  Google Scholar 

  169. Pan B, Zhao MH, Chen Z, Lu L, Wang Y, Shi DW et al (2007) Inhibitory effects of resistin-13-peptide on the proliferation, adhesion, and invasion of MDA-MB-231 in human breast carcinoma cells. Endocrine Relat Cancer 14(4):1063–1071

    Article  CAS  Google Scholar 

  170. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2(3):161–174

    Article  CAS  PubMed  Google Scholar 

  171. Yang CC, Chang SF, Chao JK, Lai YL, Chang WE, Hsu WH et al (2014) Activation of AMP-activated protein kinase attenuates hepatocellular carcinoma cell adhesion stimulated by adipokine resistin. BMC Cancer 14:112

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  172. Tsai CH, Tsai HC, Huang HN, Hung CH, Hsu CJ, Fong YC et al (2015) Resistin promotes tumor metastasis by down-regulation of miR-519d through the AMPK/p38 signaling pathway in human chondrosarcoma cells. Oncotarget 6(1):258–270

    PubMed  Google Scholar 

  173. Di Simone N, Di Nicuolo F, Sanguinetti M, Castellani R, D'Asta M, Caforio L et al (2006) Resistin regulates human choriocarcinoma cell invasive behaviour and endothelial cell angiogenic processes. J Endocrinol 189(3):691–699

    Article  PubMed  CAS  Google Scholar 

  174. Hsieh YY, Shen CH, Huang WS, Chin CC, Kuo YH, Hsieh MC et al (2014) Resistin-induced stromal cell-derived factor-1 expression through Toll-like receptor 4 and activation of p38 MAPK/ NFkappaB signaling pathway in gastric cancer cells. J Biomed Sci 21:59

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  175. Deshmukh SK, Srivastava SK, Bhardwaj A, Singh AP, Tyagi N, Marimuthu S et al (2015) Resistin and interleukin-6 exhibit racially-disparate expression in breast cancer patients, display molecular association and promote growth and aggressiveness of tumor cells through STAT3 activation. Oncotarget 6(13):11231–11241

    Article  PubMed  PubMed Central  Google Scholar 

  176. Ghaemmaghami S, Mohaddes SM, Hedayati M, Gorgian Mohammadi M, Dehbashi G (2013) Resistin and visfatin expression in HCT-116 colorectal cancer cell line. Int J Mol Cell Med 2(3):143–150

    PubMed  PubMed Central  Google Scholar 

  177. Rak A, Drwal E, Wrobel A, Gregoraszczuk EL (2015) Resistin is a survival factor for porcine ovarian follicular cells. Reproduction 150(4):343–55

    Article  CAS  PubMed  Google Scholar 

  178. Kushiro K, Nunez NP (2011) Ob/ob serum promotes a mesenchymal cell phenotype in B16BL6 melanoma cells. Clin Exp Metastasis 28(8):877–886

    Article  CAS  PubMed  Google Scholar 

  179. Pang L, Zhang Y, Yu Y, Zhang S (2013) Resistin promotes the expression of vascular endothelial growth factor in ovary carcinoma cells. Int J Mol Sci 14(5):9751–9766

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  180. Mu H, Ohashi R, Yan S, Chai H, Yang H, Lin P et al (2006) Adipokine resistin promotes in vitro angiogenesis of human endothelial cells. Cardiovasc Res 70(1):146–157

    Article  CAS  PubMed  Google Scholar 

  181. Kunnari AM, Savolainen ER, Ukkola OH, Kesaniemi YA, Jokela MA (2009) The expression of human resistin in different leucocyte lineages is modulated by LPS and TNFalpha. Regul Pept 157(1-3):57–63

    Article  CAS  PubMed  Google Scholar 

  182. Butler J, Kalogeropoulos A, Georgiopoulou V, de Rekeneire N, Rodondi N, Smith AL et al (2009) Serum resistin concentrations and risk of new onset heart failure in older persons: the health, aging, and body composition (Health ABC) study. Arterioscler Thromb Vasc Biol 29(7):1144–1149

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  183. Frankel DS, Vasan RS, D'Agostino RB Sr, Benjamin EJ, Levy D, Wang TJ et al (2009) Resistin, adiponectin, and risk of heart failure the Framingham offspring study. J Am Coll Cardiol 53(9):754–762

    Article  CAS  PubMed  Google Scholar 

  184. Kim M, Oh JK, Sakata S, Liang I, Park W, Hajjar RJ et al (2008) Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 45(2):270–280

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  185. Singal PK, Iliskovic N (1998) Doxorubicin-induced cardiomyopathy. N Engl J Med 339(13):900–905

    Article  CAS  PubMed  Google Scholar 

  186. Schwartz DR, Briggs ER, Qatanani M, Sawaya H, Sebag IA, Picard MH et al (2013) Human resistin in chemotherapy-induced heart failure in humanized male mice and in women treated for breast cancer. Endocrinology 154(11):4206–4214

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  187. Marseglia L, Manti S, D'Angelo G, Nicotera A, Parisi E, Di Rosa G et al (2015) Oxidative stress in obesity: a critical component in human diseases. Int J Mol Sci 16(1):378–400

    Article  CAS  Google Scholar 

  188. Dupont J, Reverchon M, Cloix L, Froment P, Rame C (2012) Involvement of adipokines, AMPK, PI3K and the PPAR signaling pathways in ovarian follicle development and cancer. Int J Dev Biol 56(10-12):959–967

    Article  CAS  PubMed  Google Scholar 

  189. Carmina E (2013) Obesity, adipokines and metabolic syndrome in polycystic ovary syndrome. Front Horm Res 40:40–50

    Article  CAS  PubMed  Google Scholar 

  190. Duan XF, Tang P, Li Q, Yu ZT (2013) Obesity, adipokines and hepatocellular carcinoma. Int J Cancer 133(8):1776–1783

    Article  CAS  PubMed  Google Scholar 

  191. Fontana A, Spadaro S, Copetti M, Spoto B, Salvemini L, Pizzini P et al (2015) Association between resistin levels and all-cause and cardiovascular mortality: a new study and a systematic review and meta-analysis. PLoS One 10(3), e0120419

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  192. DiCarlo J, Agarwal-Hashmi R, Shah A, Kim P, Craveiro L, Killen R et al (2014) Cytokine and chemokine patterns across 100 days after hematopoietic stem cell transplantation in children. Biol Blood Marrow Transplant 20(3):361–369

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. OHSU-PSU School of Public Health, Oregon Health and Science University, 3181 SW Sam Jackson Park Road, Mail Code GH153, Portland, OR, 97239, USA

    Zhenzhen Zhang Ph.D. M.P.H. & Jackilen Shannon Ph.D. R.D.

  2. Department of Medicine, Columbia University Medical Center, 630 West 168th Street, PS11-420, New York, NY, 10032, USA

    Hanrui Zhang B.Med. Ph.D.

Authors
  1. Zhenzhen Zhang Ph.D. M.P.H.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jackilen Shannon Ph.D. R.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hanrui Zhang B.Med. Ph.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hanrui Zhang B.Med. Ph.D. .

Editor information

Editors and Affiliations

  1. Department of Cellular and Molecular Medicine, Cleveland Clinic Lerner Research Institute, Cleveland, Ohio, USA

    Ofer Reizes

  2. Center for Science, Health and Society, Case Western Reserve University, Cleveland, Ohio, USA

    Nathan A. Berger

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zhang, Z., Shannon, J., Zhang, H. (2017). Resistin, Obesity, and Cancer. In: Reizes, O., Berger, N. (eds) Adipocytokines, Energy Balance, and Cancer. Energy Balance and Cancer, vol 12. Springer, Cham. https://doi.org/10.1007/978-3-319-41677-9_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-41677-9_9

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-41675-5

  • Online ISBN: 978-3-319-41677-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation